UBS AM
KNSA icon

UBS AM’s Kiniksa Pharmaceuticals KNSA Stock Holding History

UBS AM’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14M Buy
44,525
+2,123
+5% +$94K ﹤0.01% 2012
2025
Q4 		$1.75M Sell
42,402
-13,117
-24% -$526K ﹤0.01% 1939
2025
Q3 		$2.16M Sell
55,519
-49,186
-47% -$1.6M ﹤0.01% 1714
2025
Q2 		$2.9M Buy
104,705
+48,729
+87% +$1.24M ﹤0.01% 1973
2025
Q1 		$1.24M Sell
55,976
-715
-1% -$14.7K ﹤0.01% 2216
2024
Q4 		$1.12M Buy
56,691
+12,462
+28% +$284K ﹤0.01% 2314
2024
Q3 		$1.11M Buy
+44,229
New +$1.08M ﹤0.01% 2350
2024
Q2 		– Sell
-10,608
Closed -$209K – 2851
2024
Q1 		$209K Hold
10,608
– – ﹤0.01% 2457
2023
Q4 		$186K Hold
10,608
– – ﹤0.01% 2499
2023
Q3 		$184K Hold
10,608
– – ﹤0.01% 2524
2023
Q2 		$114K Hold
10,608
– – ﹤0.01% 2634
2023
Q1 		$114K Sell
10,608
-19,400
-65% -$256K ﹤0.01% 2634
2022
Q4 		$450K Hold
30,008
– – ﹤0.01% 2212
2022
Q3 		$385K Sell
30,008
-5,482
-15% -$62.5K ﹤0.01% 2436
2022
Q2 		$344K Hold
35,490
– – ﹤0.01% 2431
2022
Q1 		$353K Hold
35,490
– – ﹤0.01% 2552
2021
Q4 		$418K Hold
35,490
– – ﹤0.01% 2615
2021
Q3 		$404K Buy
+35,490
New +$462K ﹤0.01% 2559

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

UBS AM's KNSA Position: Q1 2026 in Review

UBS AM increased its Kiniksa Pharmaceuticals (KNSA) stake by 5% in Q1 2026, buying an estimated $94K and bringing the position to 44,525 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

UBS AM first reported a position in KNSA in Q3 2021 and has held it in 18 quarters since. The position peaked at $2.9M in Q2 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • UBS AM held 44,525 shares of Kiniksa Pharmaceuticals worth $2.14M as of Q1 2026.
  • UBS AM bought 2,123 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $94K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2012 holding.
  • UBS AM first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • UBS AM's Kiniksa Pharmaceuticals position peaked at $2.9M in Q2 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.